MacroGenics Inc. (MGNX) - Debt to Equity

MGNX (MacroGenics, Inc.) - company brandmark

MacroGenics, Inc. (MGNX) operations are constrained by global supply chain disruption risks and the complexities of patent protection amid geopolitical tensions. This chart illustrating the asset's market value with the 4.86 metric reflects the firm's financial standing. The business relies on DART technology to create tumor-destroying antibodies. Competitiveness is sustained by unique developments in targeted therapy, despite the volatility of clinical trial results.

MGNX: macrogenics.com Debt to Capital 07/04/2022 - 10/29/2026

MGNX (MacroGenics Inc.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Stock Price MacroGenics|MGNX - Price Target Chart
- market capitalization indicators:
Market Value MacroGenics|MGNX - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share MacroGenics|MGNX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio macrogenics.com|MGNX - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity MacroGenics, Inc.|MGNX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio MacroGenics, Inc.|MGNX - Company Cumulative Indebtedness|Debt to Book Value MacroGenics|MGNX - Company Long-Term Loans and Borrowings|Company Short-Term Debts MacroGenics|Quick Ratio macrogenics.com
- earnings and valuation multiples information:
MGNX - Net Profit
Fundamental valuation:MacroGenics
Core merchandise of macrogenics.com

Investors are assessing the resilience of MacroGenics, Inc. (MGNX) by analyzing the total liabilities-to-equity ratio, which determines the business's degree of dependence on borrowed funds. By examining the debt-to-equity trend, one can understand how effectively the experienced management balances costly antibody development with the acquisition of external financing through licensing deals to avoid a critical debt load.

Competitor analysis for MacroGenics, Inc.

OLMA (Olema) - Total Debt to Capital|Debt to Equity PBYI|Debt to Equity Greenwich LifeSciences, Inc (GLSI)|ZNTL (Zentalis Pharma) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital PSTV (Plus Therapeutics)|Processa Pharmaceuticals Inc. (PCSA) - Debt to Capital|Eagle Pharma - Total Debt to Capital